Market Insights

• Biosimilars - Over $100 billion of Biologics sales will go off-patent in 2012-2018.
• Over 85%-90% of the biologics patents will go off patent in next 10 years.
• By 2020, approx. 85 major biologics will be off–patent opening new and major opportunities.
• A recent study has shown that with Biosimilars, Europe can save 33 billion euros in eight EU countries. (May, 2012)
• European Authorities have taken a lead on approval of Biosimilars.
• 16 Biosimilars are approved in Europe. New approvals may come further in 2013-14.
• New Law in USA- Biologics Price Competition and Innovation Act (enacted in 2010). Based on this law, the US- FDA has the authority to approve similar versions of biologic products (“biosimilars”).
• US- FDA issued draft guidelines for biosimilars approval (2012).

• By 2030, there will be 436 million diabetics worldwide.
• By 2030, India with 87 million people and China with 64 million inhabitants will be most diabetic nations.
• Diabetes is a chronic disease leading to life-long use of medicines.
• Diabetes markets to grow as prevalence of over-weight and obesity is increasing rapidly.
• According to an estimate, obese population in China tripled from 2002 to 2010.
• US markets are major markets. Diabetes affects more than 32 million Americans today. These numbers are expected to grow to 53 million in 2025.
• The annual budgets of medical and indirect society costs are expected to rise from 300 Billion USD to 515 Billion USD in 2025.
• Demand for Diabetes products are growing as life expectancy is also growing.
• By 2050, life expectancy is expected to increase and reach over 80 years. This will further fuel growth and needs of diabetes products globally.
• Insulin markets are growing with sustained double digit growth.
• Demand of modern Insulins is growing more rapidly and modern Insulins are replacing normal Insulin and animal Insulins.
• Total Sales of Diabetes products are expected to cross sales of 32 billion dollars a year.
• A major opportunity lies in the emerging markets for insulin, especially in the BRIC nations.
• With large share of undiagnosed population and low number of people on insulin; growth prospects are promising. It is expected that the market will advance at a CAGR of around 10% during 2012-2015 to reach US$ 23.8 Billion.
• Anti-diabetic therapies are forecast to become the highest revenue generator in 2017.
• 50% of the top 10 brands in 2017 are forecast to be anti-diabetics. - Datamonitor Report.

• Osteoporosis is often called the "silent disease" because bone loss occurs without symptoms. It is characterized by low bone mass and deterioration of bone tissue, leading to bone fragility and a consequent increase in risk of fracture.
• As per International Osteoporosis Foundation census, more than 200 million people in the world are affected by osteoporosis, of which about 80% are women.
• Osteoporosis represents an implacable epidemic growing rapidly in regions of North America, Europe, and Japan.
• Brazil, Russia, India and China are the fastest growing nations, driving a combined CAGR of 17%.
• The Chinese Osteoporosis drug market is expected to grow at a CAGR of 13.5% from 2010 to 2015. China Osteoporosis market will be worth USD 2.5 billion in 2015.
• Osteoporosis prevalence is expected to increase due to the general aging population. In addition to increasing awareness, diagnosis and treatment.
• By 2020, the total male and female osteoporosis population is forecast to increase by 16.0% to reach 188 million patients across the seven major markets alone.
• There are four Osteoporosis Drug Class (Bisphosphonate, SERM, PTH and Calcitonin) market.
• Top Nine Osteoporosis Drug Brands are –FORTEO, PROLIA, Fosamax, Actonel, Reclast, Boniva, Evista, Viviant/Conbriza and Miacalcin.
• A rapid uptake of Forteo/Forsteo and Prolia make these two products the most significant market drivers of osteoporosis therapeutics market. 
• Global osteoporosis market is expected to reach 16 Billion by 2015.
• Teriparatide- Sales are expected to reach US 2.0 billion $ / year in 2019.